BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 1,130,000 shares, a drop of 5.8% from the May 31st total of 1,200,000 shares. Based on an average daily trading volume, of 644,900 shares, the short-interest ratio is currently 1.8 days.

BioVie Stock Up 2.8 %

BIVI opened at $0.42 on Thursday. BioVie has a 52 week low of $0.40 and a 52 week high of $5.82. The business’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.78. The firm has a market cap of $25.43 million, a price-to-earnings ratio of -0.44 and a beta of 0.74.

BioVie (NASDAQ:BIVI) last announced its earnings results on Tuesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, ThinkEquity assumed coverage on shares of BioVie in a research report on Monday. They issued a “buy” rating and a $3.00 price target for the company.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BioVie stock. Sheaff Brock Investment Advisors LLC lifted its holdings in shares of BioVie Inc. (NASDAQ:BIVI) by 276.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,400 shares of the company’s stock after buying an additional 37,762 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.13% of BioVie worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.